BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28780300)

  • 21. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
    de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
    Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study.
    Okita K; Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
    Urol Oncol; 2021 Dec; 39(12):836.e11-836.e17. PubMed ID: 34544649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
    Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
    Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic model of upfront cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors and/or targeted agents.
    Teishima J; Goto K; Sekino Y; Mita K; Hayashi T; Hasegawa Y; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Kobayashi K; Asano K; Hinata N
    Int Urol Nephrol; 2022 Jun; 54(6):1225-1232. PubMed ID: 35314918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
    Dariane C; Timsit MO; Méjean A
    Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).
    Marchioni M; Kriegmair M; Heck M; Amiel T; Porpiglia F; Ceccucci E; Campi R; Minervini A; Mari A; Van Bruwaene S; Linares E; Hevia V; Musquera M; D'Anna M; Derweesh I; Bradshaw A; Autorino R; Guruli G; Veccia A; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Palumbo C; Klatte T; Erdem S; Mir MC;
    Eur Urol Oncol; 2021 Apr; 4(2):256-263. PubMed ID: 33384274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.
    Lenis AT; Salmasi AH; Donin NM; Faiena I; Johnson DC; Drakaki A; Gollapudi K; Blumberg J; Belldegrun AS; Pantuck AJ; Chamie K
    Urol Oncol; 2018 Feb; 36(2):78.e21-78.e28. PubMed ID: 29128421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
    DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
    Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
    Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
    Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
    Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers.
    Dragomir A; Nazha S; Tanguay S; Breau RH; Bhindi B; Rendon RA; Kapoor A; Hotte SJ; Basappa N; Fairey A; So AI; Kollmannsberger C; Finelli A; Hansen A; Canil C; Heng D; Lattouf JB; Bjarnason G; Power N; Pouliot F; Wood LA
    Eur Urol Focus; 2022 Nov; 8(6):1703-1710. PubMed ID: 34736870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
    Roussel E; Campi R; Larcher A; Verbiest A; Antonelli A; Palumbo C; Derweesh I; Ghali F; Bradshaw A; Meagher MF; Heck M; Amiel T; Kriegmair MC; Rubio J; Musquera M; D'Anna M; Autorino R; Guruli G; Veccia A; Linares-Espinos E; Van Bruwaene S; Hevia V; Porpiglia F; Checcucci E; Minervini A; Mari A; Pavan N; Claps F; Marchioni M; Capitanio U; Beuselinck B; Mir MC; Albersen M;
    Eur Urol Oncol; 2020 Aug; 3(4):523-529. PubMed ID: 32414697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma.
    Andrews JR; Lohse CM; Boorjian SA; Leibovich BC; Thompson H; Costello BA; Bhindi B
    Urol Oncol; 2022 Apr; 40(4):166.e1-166.e8. PubMed ID: 35168879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
    Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
    Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
    Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
    Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
    Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
    Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.